Front Row Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Front Row Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.06K	Hold	57	–	–	﹤0.01%	526
2025 Q4	$889	Hold	57	–	–	﹤0.01%	512
2025 Q3	$834	Sell	57 -29	-34%	-$431	﹤0.01%	512
2025 Q2	$1.33K	Sell	86 -59	-41%	-$872	﹤0.01%	491
2025 Q1	$2.16K	Hold	145	–	–	﹤0.01%	446
2024 Q4	$1.92K	Hold	145	–	–	﹤0.01%	446
2024 Q3	$2.06K	Sell	145 -315	-68%	-$4.47K	﹤0.01%	444
2024 Q2	$5.95K	Hold	460	–	–	﹤0.01%	695
2024 Q1	$6.39K	Buy	460 +315	+217%	+$4.58K	﹤0.01%	684
2023 Q4	$2.07K	Sell	145 -315	-68%	-$4.47K	﹤0.01%	413
2023 Q3	$7.12K	Hold	460	–	–	﹤0.01%	596
2023 Q2	$7K	Hold	460	–	–	﹤0.01%	609
2023 Q1	$8K	Buy	460 +145	+46%	+$2.31K	﹤0.01%	581
2022 Q4	$5K	Sell	315 -145	-32%	-$2.02K	﹤0.01%	655
2022 Q3	$6K	Hold	460	–	–	﹤0.01%	625
2022 Q2	$6K	Hold	460	–	–	﹤0.01%	641
2022 Q1	$7K	Hold	460	–	–	﹤0.01%	650
2021 Q4	$6K	Hold	460	–	–	﹤0.01%	717
2021 Q3	$8K	Hold	460	–	–	﹤0.01%	636
2021 Q2	$8K	Sell	460 -767	-63%	-$13.1K	﹤0.01%	630
2021 Q1	$22K	Hold	1,227	–	–	0.01%	388
2020 Q4	$22K	Hold	1,227	–	–	0.01%	372
2020 Q3	$22K	Sell	1,227 -196	-14%	-$3.57K	0.01%	368
2020 Q2	$26K	Hold	1,423	–	–	0.02%	298
2020 Q1	$26K	Buy	1,423 +134	+10%	+$2.43K	0.02%	295
2019 Q4	$25K	Hold	1,289	–	–	0.02%	298
2019 Q3	$22K	Sell	1,289 -44	-3%	-$761	0.02%	307
2019 Q2	$24K	Buy	1,333 +255	+24%	+$4.64K	0.02%	292
2019 Q1	$22K	Buy	+1,078	New	+$21.7K	0.02%	303

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Front Row Advisors's TAK Position: Q1 2026 in Review

Front Row Advisors held its Takeda Pharmaceutical (TAK) position steady in Q1 2026 at 57 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

Front Row Advisors first reported a position in TAK in Q1 2019 and has held it in 29 quarters since. The position peaked at $26K in Q2 2020. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Front Row Advisors held 57 shares of Takeda Pharmaceutical worth $1.06K as of Q1 2026.
Front Row Advisors left its Takeda Pharmaceutical share count unchanged in Q1 2026.
Takeda Pharmaceutical made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #526 holding.
Front Row Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
Front Row Advisors's Takeda Pharmaceutical position peaked at $26K in Q2 2020.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.